Divi’s Lab Q2: Large Cap Pharma Co Reports 29% YoY Fall In Net Profit

Large cap pharmaceuticals company Divi's Laboratories Ltd on Monday announced a decline of 29% in its consolidated net profit at Rs 348 crore for the quarter ended September 30, 2023 as compared to Rs 493 crore declared an year ago. The pharma company's revenue from operations soared 3% year-on-year (YoY) to Rs 1909 crore for the July to September quarter as against Rs 1855 crore declared in the corresponding quarter of last year. Last trading price of Divi's Laboratories share on BSE is Rs 3505.70 per share. Divi's Laboratories shares rallied 4.65% despite dip in the consolidated net profit.

Divi's Laboratories shares offered a rally of over 3% in last 1-week. Divi's Laboratories stock fell over 6% in last 3-months, gained 4% YTD, fell 6% in last 1-year, and again declined by 32% in last 2-years. In last 3-years, Divi's Laboratories stock surged over 8% and gained more than 137% in last 5-years. Its 52-week high price is Rs 3949.00 per share and 52-week low price is Rs 2730.00 per share, respectively. The company's market capitalisation is Rs 93,065.32 crore.

The company reported its consolidated EBITDA for the quarter under consideration at Rs 479 crore. Margins were announced at 25.1%.

Divi's Laboratories profit before tax (PBT) for the September quarter declared at Rs 469 crore, down 24% as against the profit before tax of Rs 615 crore declared in the corresponding quarter of last year.

The company declared the consolidated total income at Rs 1995 crore, up 3% YoY in the September quarter as compared to Rs 1935 crore in the year-ago period.

Divi's Laboratories' PAT for the first half arrived at Rs 704 crore, down 41% as compared with Rs 1,196 crore for the corresponding period of last year. For the current half-year, the company had a forex gain of Rs 14 crore as against the gain of Rs 87 crore during the corresponding period last year.

Divi's Laboratories About: Established in the year 1990, Divi's is a leading manufacturer of Active Pharmaceutical Ingredients offering high quality products to over 95 countries. Divi's manufactures Generic APIs, Nutraceutical Ingredients and offers Custom Synthesis of APIs to Big Pharma providing a competitive advantage over the entire life cycle of the products, according to its official website.